Drug Trial Radar · NCT00438113
Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF
Last checked: Nov 20, 2026Latest source record: Jun 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
184
Actual
Start
Dec 2009
Primary completion
Sep 2016
Study completion Sep 2016
Sponsor
- Lead sponsor
- Nova Scotia Health AuthorityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nova Scotia Health Research Foundation
- First posted
- Feb 21, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP control to investigate this.
Conditions
- Atrial Fibrillation
Interventions
Aggressive Blood Pressure controlDrug
Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to symptomatic AF/atrial tachycardia (AT)/atrial flutter (AFl) lasting > 30 seconds more than 3 months post ablation.Time frame: at least 3 months post catheter ablation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
QE II Health Sciences Centre
Halifax, Nova Scotia, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.